<DOC>
	<DOCNO>NCT02397889</DOCNO>
	<brief_summary>The purpose study study new way treat post-traumatic stress disorder ( PTSD ) . Current treatment PTSD work everyone take time determine whether person respond choose treatment . The purpose study see whether ketamine , give repeatedly intravenously produce quick persistent improvement PTSD symptom . At high dos , ketamine use many year anesthetic medical procedure , low dos may effective treatment patient major depression PTSD . Ketamine give PTSD investigational , mean FDA yet approve drug treat condition . In study , effect ketamine compare midazolam . Midazolam similar acute anesthetic effect compare ketamine show treat alleviate symptom PTSD . This make midazolam appropriate substance gauge whether ketamine treat alleviate PTSD symptom thereby act call active control .</brief_summary>
	<brief_title>Repeated-Dose Intravenous Ketamine PTSD</brief_title>
	<detailed_description>Ketamine approve medication several country induction general anesthesia use adjunct anesthetic . Intravenous ketamine develop test treatment posttraumatic stress disorder ( PTSD ) . All subject administer study medication study anesthesiologist direct supervision investigator designee . On dose day , subject must remain clinical site least 4 hour post-dose ( longer require study procedure ) accompany responsible adult discharge clinical site . The end study occur last subject trial complete his/her last study assessment .</detailed_description>
	<mesh_term>Stress Disorders , Traumatic</mesh_term>
	<mesh_term>Stress Disorders , Post-Traumatic</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Men woman , 1865 year age ; Participants must level understanding sufficient agree test examination require protocol must sign write informed consent document ; Participants must fulfill DSM5 criterion current civilian combatrelated PTSD Women must use medically accept reliable mean contraception ( use oral contraceptive medication , must also use barrier contraceptive ) childbearing potential ( i.e. , surgically sterile , postmenopausal least one year ) ; Women childbearing potential must negative pregnancy test screen prior intravenous infusion ; Participants must able identify family member , physician , friend ( i.e . someone know well ) participate Treatment Contract ( e.g . contact study physician behalf case manic symptom suicidal thought develop ) . Exclusion criterion : Women plan become pregnant , pregnant breastfeed Serious , unstable medical illness hepatic , renal , gastroenterologic , respiratory , cardiovascular , endocrinologic , neurologic , immunologic , hematologic disease , include gastroesophageal reflux disease , obstructive sleep apnea , history difficulty airway management previous anesthetic , ischemic heart disease uncontrolled hypertension , history severe head injury ; Clinically significant abnormal finding laboratory parameter , physical examination , ECG ; Renal impairment , reflect BUN &gt; 20 mg/dL , and/or creatinin clearance &gt; 1.3 mg/dL ; Thyroid impairment , reflect TSH &gt; 4.2 mU/L Patients uncorrected hypothyroidism hyperthyroidism ; Hormonal treatment ( e.g. , estrogen ) start 3 month prior first infusion day ; Use evidencebased individual psychotherapy ( prolonged exposure ) study ; History autism , mental retardation , pervasive developmental disorder , Tourette 's syndrome ; History one seizures without clear resolve etiology ; History ( hypo ) mania ; Past current presence psychotic symptom , diagnosis lifetime psychotic disorder include schizophrenia schizoaffective disorder ; Drug alcohol abuse dependence within precede 3 month Previous recreational use ketamine PCP ; Current diagnosis bulimia nervosa anorexia nervosa ; Diagnosis schizotypal antisocial personality disorder Patients judge clinically serious imminent suicidal homicidal risk . A blood pressure one reading 160/90 two separate reading 140/90 screen baseline visit Patients report current treatment benzodiazepine , opioid medication , mood stabilizer ( valproic acid lithium ) within 2 week prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>posttraumatic stress disorder</keyword>
	<keyword>PTSD</keyword>
	<keyword>ketamine</keyword>
	<keyword>trauma</keyword>
	<keyword>treatment</keyword>
	<keyword>New York</keyword>
	<keyword>NYC</keyword>
</DOC>